While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

The funding was meant to help the U.S. prepare for pandemics triggered by avian flu strains, but now leaves the future of ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Keros will also stop work on a cardiovascular disease drug. Elsewhere, Stealth Biotherapeutics and Taysha Gene Therapies each ...

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study ...

After a three-year drought, the industry is questioning whether the window for medtech public offerings is open following a ...

Commissioner Martin Makary and two of his deputies aim to meet with drugmaker CEOs to discuss how the agency can “modernize” ...

The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...